Seasoned finance and operations leader will focus on expanding cardiac CT access for clinics and cardiology practices nationwide.
Caesarea, Israel – Feb. 3, 2025 – Arineta, a leader in advancing cardiovascular imaging solutions, today announced the appointment of Einav Ehre by its board of directors as interim Chief Executive Officer, effective immediately. Ehre will continue to serve in his current roles as the company’s Chief Operating Officer and Chief Financial Officer.
Ehre is one of Arineta’s founding executives and a leader at the company since 2007. Over nearly two decades, he has played an instrumental role in scaling Arineta’s global operations, building the company’s organizational structure, and overseeing finance, accounting, HR, operations, strategic planning, and executive leadership across the U.S., Israel, and China.
As interim CEO, Ehre will reinforce Arineta’s strategy to broaden access to cardiac CT imaging, particularly for clinics and smaller cardiology practices. His priorities include advancing the company’s commitment to AI-guided innovation, strengthening reimbursement pathways, and helping providers adopt advanced CT technology in a financially sustainable way. With a focus on the growing role of AI in improving efficiency, Ehre is dedicated to streamlining the integration of advanced image analysis while maintaining high standards for image quality and clinical value. He also remains focused on supporting the organization and its employees as the company moves into its next phase of growth.
“With this technology and the responsible use of AI, I believe the team at Arineta will continue to be a leader in changing how heart disease is managed and ensuring care is accessible to all,” said Ehre. “Intervention shouldn’t happen only after adverse events, and if we can help clinicians identify risk sooner, it becomes a disease we can control.”
Arineta’s flagship systems, SpotLight and SpotLight™ Duo, are the world’s first dedicated cardiovascular CT scanners, designed specifically for single-beat, whole-heart imaging. By reducing the physical footprint and cost typically associated with cardiac CT, Arineta is improving access to advanced cardiac diagnostics, allowing for broader use by providers to reach more patients.
For more information about Arineta and its solutions, visit arineta.com.
About Arineta
Arineta, based in Israel, specializes in developing innovative cardiovascular imaging solutions. The company is committed to advancing cardiac CT as the front-line non-invasive method for diagnosing, planning therapy, and monitoring cardiovascular disease, the leading cause of death and healthcare costs worldwide. Arineta’s flagship product, the SpotLight™ Duo, based on the company’s proprietary Stereo CT technology, is the world’s first dedicated single-heartbeat, whole-heart cardiovascular and thoracic CT scanner. Building on its history of medical imaging innovation that began in Israel in the 1970s, Arineta’s team includes the inventors of multi-slice spiral CT technology, still the cornerstone of CT imaging, and several other key technologies.
